Genetic polymorphisms of hemostasis genes and primary outcome of very low birth weight infants

Pediatrics

Volumn 118, Issue 2, 2006, Pages 683-689

  Härtel, Christoph ^a   König, Inke ^a   Köster, Stefan ^a   Kattner, Evelyn ^b   Kuhls, Eckhardt ^c   Küster, Helmut ^d   Möller, Jens ^e   Müller, Dirk ^f   Kribs, Angela ^g   Segerer, Hugo ^h   Wieg, Christian ⁱ   Herting, Egbert ^a   Göpel, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Kinderklinik auf der Bult   (Germany)

^c OLGAHOSPITAL   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e Childrens Hospital Saarbrucken   (Germany)

^f Children's Hospital   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h Kinderklinik St Hedwig   (Germany)

ⁱ University of Applied Science   (Germany)

Author keywords

Hemostasis genes; Outcome; Polymorphism; VLBW

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

ARTICLE; BRAIN HEMORRHAGE; BRAIN PERIVENTRICULAR LEUKOMALACIA; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMOSTASIS; HOSPITAL CARE; HUMAN; HUMAN TISSUE; INFANT; LEUKOMALACIA; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREMATURE LABOR; PRIORITY JOURNAL; RESTRICTION MAPPING; SEPSIS; VERY LOW BIRTH WEIGHT; 3' UNTRANSLATED REGION; ACTIVATED PROTEIN C RESISTANCE; ARTIFICIAL VENTILATION; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CATHETERIZATION; ENCEPHALOMALACIA; GENE DELETION; GENETICS; GERMANY; NEWBORN; PREMATURITY; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICS; SURGERY; THROMBOPHILIA; UTILIZATION REVIEW;

3' UNTRANSLATED REGIONS; ACTIVATED PROTEIN C RESISTANCE; BRONCHOPULMONARY DYSPLASIA; CATHETERIZATION; CEREBRAL HEMORRHAGE; COHORT STUDIES; FACTOR V; FACTOR VII; FACTOR VII DEFICIENCY; FACTOR XIII; FACTOR XIII DEFICIENCY; GENOTYPE; GERMANY; HEMORRHAGIC DISORDERS; HEMOSTASIS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; LEUKOMALACIA, PERIVENTRICULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTHROMBIN; RESPIRATION, ARTIFICIAL; SEPSIS; SEQUENCE DELETION; SURGICAL PROCEDURES, OPERATIVE; THROMBOPHILIA;

EID: 33748433295     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2670     Document Type: Article

References (32)

1. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;13:880-881
2. Corral J, Iniesta JA, Gonzalez-Conejero R, Villalon M, Vicente V. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood. 2001;97:2979-2982
3. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231
4. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biochem Phys. 2004;112:213-218
5. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743-754
6. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Hemost. 1998;79:8-13
7. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood. 1999;93:906-908
8. Elbaz A, Pirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood. 2000;95:586-691
9. Franco RF, Reitsma PH, Lourenco D, et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Hemost. 1999;81:676-679
10. Mariani G, Lapecorella M, Dolce A. Steps towards an effective treatment strategy in congenital factor vii deficiency. Semin Hematol. 2006;43S1:S42-S47
11. Mariani G, Herrmann FH, Dolce A, et al., for the International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Hemost. 2005;93:481-487
12. Liu Y, Heng CK, Saha N, Hong S, Low PS. Genotype associations of factor VII gene with plasma factor VII coagulant activity and antigen levels in healthy Chinese. Blood Coagul Fibrinolysis. 2002;13:217-224
13. Rubattu S, Di Angelantonio E, Nitsch D, et al. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Hemost. 2005;93:1095-1100
14. Bozzini C, Girelli D, Bernardi F, et al. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thromb Hemost. 2004;92:541-549
15. De Maat MPM, Green F, de Knijff P, Jespersen J, Kluft C. Factor VII Polymorphisms in populations with different risks of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997;17:1918-1923
16. Humphries S, Temple A, Lane A, Green F, Cooper J, Miller G. Low plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (-323) insertion than the glutamine 353 variant. Thromb Hemost. 1996;75:567-572
17. Kudaravalli R, Tidd T, Pinotti M, et al. Polymorphic changes in the 5′flanking region of factor VII have a combined effect on promoter strength. Thromb Hemost. 2002;88:763-767
18. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774-780
19. Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet. 1999;353:1411-1412
20. Petäjä J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res. 2001;49:643-646
21. Komlosi K, Havasi V, Bene J, et al. Increased prevalence of factor V Leiden mutation in premature but not in full-term infants with grade I intracranial hemorrhage. Biol Neonate. 2005;87:56-59
22. Nelson KB, Dambrosia JM, Iovannisci DM, Cheng S, Grether JK, Lammer E. Genetic polymorphisms and cerebral palsy in very preterm infants. Pediatr Res. 2005;57:494-499
23. Göpel W, Kattner E, Seidenberg J, Kohlmann T, Segerer H, Möller J. The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500g. J Pediatr. 2002;140:688-692
24. Härtel C, von Otte S, Koch J, et al. Polymorphisms of hemostasis genes as risk factors for preterm birth. Thromb Haemost. 2005;94:88-92
25. Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Hemost. 1997;78:1157-1158
26. Van Hylckama Vlieg A, Komanasin N, Ariens RA, et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Hematol. 2002;119:169-175
27. Leviton A, Dammann O. Coagulation, inflammation, and the risk of neonatal white matter damage. Pediatr Res. 2004;55:541-545
28. Göpel W, Gortner L, Kohlmann T, Schultz C, Möller J. Low prevalence of large intraventricular hemorrhage in very low birth weight infants carrying the factor V Leiden or prothrombin G20210A mutation. Acta Paediatr. 2001;90:1021-1024
29. Kenet G, Mayan-Metzer A, Rosenberg N, et al. Thrombophilia does not increase risk for neonatal complications in preterm infants. Thromb Hemost. 2003;90:823-828
30. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP. Importance of hemostatic gene polymorphisms for susceptibility to ad outcome of severe sepsis. Crit Care Med. 2004;32(suppl 5):S313-S319
31. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517-1532
32. Kerlin BA, Yan SB, Istermann BH, et al. Survival advantage associated with heterozygous factor v Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102:3085-4002